Product
Fc-Engager Platform: Antigen-Specific Immune Tolerance
Early-stage biologics designed to promote durable, antigen-specific immune tolerance and reduce the need for broad immunosuppression.
- Medtech
- Biotech and Lifescience
About
LoopLab Bio is a biotech startup based in Vienna, Austria, focused on developing a new class of protein-based therapeutics to treat immune-related diseases. Our mission is to create precise, well-tolerated therapies that restore balance to the immune system without broadly suppressing it.
The company’s core technology targets specific immune cells involved in harmful reactions—such as those driving autoimmune diseases, severe allergies, or anti-drug antibody responses—while preserving the body’s ability to fight infections. This approach offers a promising alternative to conventional immunosuppressants, which often come with significant side effects and safety risks.
Founded in 2023, LoopLab is advancing a pipeline of preclinical drug candidates and combines cutting-edge expertise in immunology, protein engineering, and translational science. In addition to in-house research, LoopLab is building strategic partnerships and offers BSL-2 lab and office infrastructure to support collaboration and growth.
Their ultimate goal is to redefine how immune tolerance is therapeutically induced, providing safer and more effective treatments for patients with complex immune-mediated conditions.
Business Domain / 分野
Pharmaceuticals / 医薬品
Business Type / 業種
R&D / 研究開発
Technologies / 技術
Pharmacological evaluation /薬効・薬理評価Pharmaceutical ingredients / 医薬品原料
Modalities / モダリティ
Peptide, Protein / ペプチド、タンパクAntibody drug / 抗体医薬
Disease Area / 疾患領域
Immunology / 免疫・炎症Metabolic diseases / 代謝Gastroenterology / 消化器Dermatology and sensory system / 皮膚・感覚器Rare diseases / 希少疾患
Additional questions
Researched company/organisation type / マッチングご希望企業・機関のタイプ
Companies and Academia etc. (Joint research and development purpose) / 企業やアカデミア等（共同での研究、開発を目的）Major pharma etc. (Out-licensing purpose) / 大手ファーマ等（アウトライセンスを目的）Startups, BioTech etc. (In-licensing or Partnership/Collaboration purpose) / 独自の技術やシーズを持つスタートアップ、バイオテック企業等（インライセンス、共同研究などを目的）Companies and Entities (Providing your services or technology to your clients) / 技術・サービス（研究、開発、製造等の提供を目的）CROs, CMOs, CDMOs, etc. (Partnerships)/CRO、CMO、CDMO等（インライセンス、共同研究などを目的）AI-focused companies etc. (Partnership/Collaboration about AI solutions) / AIによるソリューションをもつ企業等（インライセンス、共同研究などを目的）Consultants, Agents, etc. (Supporting overseas business development) /コンサルタント、代理店等（海外での事業展開支援などを目的）
Researched disease area / マッチングご希望の疾患領域
Infectious diseases / 感染症Immunology / 免疫・炎症Metabolic diseases / 代謝Musculoskeletal System / 筋骨格系Gastroenterology / 消化器Dermatology and sensory system / 皮膚・感覚器Rare diseases / 希少疾患Others /その他
Researched Modality / マッチングご希望のモダリティ
Peptide, Protein / ペプチド、タンパクAntibody drug / 抗体医薬Gene therapy/ 遺伝子治療
Researched Technologies / マッチングご希望の技術
Biomarkers / バイオマーカーAI・Data analysis/ AI・データ分析Others /その他
Marketplace (4)
Project cooperation
Exploratory Cooperation on Fc-Engager Platform
Seeking R&D partners to explore Fc-Engager variants in autoimmune disease, allergy, ADA prevention, transplant tolerance, and gene therapy.
- Early
- Research
- Technical
Partnership
Strategic Partnerships for Fc-Engager Development
Inviting pharma and biotech partners for co-development, licensing, and strategic alliances in immune tolerance therapies.
Investment
Investment Opportunity: Fc-Engager Immune Tolerance Platform
Seeking €30–50M Series A to advance Fc-Engager programs toward IND by 2027 and first-in-human studies by 2028.
- Startup
- Healthcare
- Biotech, Pharma and Cosmetics